Gilead keeps neutral rating from Merrill

Gilead Sciences Inc. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende. The company reported fourth-quarter 2005 earnings per share of $0.54 (non-GAAP), including a royalty adjustment related to the Tamiflu settlement with Roche. Truvada sales of $191 million were below the analyst's estimate of $205 million and consensus $197 million. Shares of the Foster City, Calif., biopharmaceutical company were up $2.97, or 5.13%, at $60.87 on volume of 11,413,605 shares versus the three-month running average of 4,648,940 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.